"RESOLVE has been outlined to better understand the regulatory networks that control the devel-opmental processes in organ repair and to identify mechanisms which cause the termination of regu-lar organ development leading to fibroproliferative wound healing. Fibroproliferative wound healing represents a major pathology in elderly people shifting regular organ development into progressive organ fibrosis with complete loss of organ function. Based on the identification of valuated molecu-lar targets of fibroproliferative repair, RESOLVE aims to create suitable treatment strategies to achieve healthy ageing in the elderly. In doing so, RESOLVE will create a significant impact on life quality of elderly people. RESOLVE’s outcomes will strengthen the competitiveness of European science and biotechnology industry and contribute to cost saving strategies in the health care sector. RESOLVE’s structured scientific approach combines as yet fragmented fields of research using model organisms which represent (a) different forms of wound healing, (b) different human diseases and (c) different genetic backgrounds, guaranteeing social and scientific relevance, modularity of re-search and the integration of existing biological knowledge, technical expertise and medical experi-ence. In addition, sequential generation of data during improvement or worsening ensures clinical relevance and leads to a stringent exploitation strategy. The sustainable outcomes of RESOLVE’s efforts will be: (A) the urgently needed diagnostic tool for fibroproliferative wound healing in various organs, (B) highly valuable transgenic animals offering test systems for fibroproliferative wound healing, and (C) a characterization of compounds capable of interfering with targets involved in fibroprolifera-tive repair."